|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
|---|---|
| Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
| ClinicalTrials.gov Identifier: | NCT00365235 |
Purpose
Familial combined hyperlipidemia (FCHL) is an inherited disorder characterized by elevated levels of cholesterol and triglycerides; it often occurs in Mexican individuals with coronary heart disease (CHD). The purpose of this study is to identify the specific genes that predispose Mexican individuals to FCHL.
| Condition |
|---|
|
Hyperlipidemia, Familial Combined Coronary Disease |
| Study Type: | Observational |
| Study Design: | Family-Based, Cross-Sectional |
| Official Title: | Genetic Susceptibility to Common Lipid Disorders in Mexico |
Whole blood sample is taken from all participants and adipose tissue sample from a subgroup.
| Estimated Enrollment: | 850 |
| Study Start Date: | July 2006 |
| Estimated Study Completion Date: | June 2010 |
| Estimated Primary Completion Date: | June 2010 (Final data collection date for primary outcome measure) |
CHD is the leading cause of death in Mexico. Dyslipidemia that is characterized by high total cholesterol, high triglycerides, and low "good" high-density lipoprotein (HDL) cholesterol is a risk factor for developing CHD. Research has shown that the Mexican population has an increased tendency towards dyslipidemia, but it is not known what genetic factors contribute to this predisposition. This study will examine the genetic basis of FCHL, which is an inherited form of dyslipidemia characterized by elevated levels of total cholesterol and triglycerides. FCHL is a major contributing factor in CHD; 20% of individuals with CHD under the age of 60 have FCHL. The purpose of this study is to identify and characterize the specific DNA sequence variations that predispose Mexican individuals to FCHL. Results of this study may aid in the development of appropriate prevention and screening techniques.
This study will enroll individuals in Mexico who have FCHL. Participants will attend one study visit for blood collection and DNA sampling. Family members of participants will be contacted and asked to provide a DNA sample also. A select group of participants will return for a second study visit for RNA sampling. Study researchers will analyze participants' DNA and RNA samples, as well as two FCHL genes identified in previous research studies.
Eligibility| Ages Eligible for Study: | 10 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Study subjects are Mexicans visiting the Dyslipidemia Clinic at the Instituto Nacional de Ciencias Medicas y Nutricion, Salvador Zubiran, Mexico City, and their family members
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Paivi E. Pajukanta, MD, PhD | 310-267-2011 | ppajukanta@mednet.ucla.edu |
| Mexico | |
| Instituto Nacional De Ciencias Medicas y Nutricion | Recruiting |
| Mexico City, Mexico, 14000 | |
| Principal Investigator: | Paivi E. Pajukanta, MD, PhD | David Geffen School of Medicine at UCLA, Department of Human Genetics |
More Information
| Responsible Party: | Department of Human Genetics, David Geffen School of Medicine at UCLA ( Paivi Pajukanta ) |
| Study ID Numbers: | 1348, R01 HL082762-01A1 |
| Study First Received: | August 16, 2006 |
| Last Updated: | February 25, 2009 |
| ClinicalTrials.gov Identifier: | NCT00365235 History of Changes |
| Health Authority: | United States: Federal Government |
|
Lipid Metabolism, Inborn Errors Arterial Occlusive Diseases Metabolic Diseases Hyperlipidemias Heart Diseases Disease Susceptibility Myocardial Ischemia Vascular Diseases Ischemia Arteriosclerosis |
Coronary Disease Metabolism, Inborn Errors Combined Hyperlipidemia, Familial Genetic Diseases, Inborn Hyperlipidemia, Familial Combined Genetic Predisposition to Disease Metabolic Disorder Dyslipidemias Coronary Artery Disease Lipid Metabolism Disorders |
|
Lipid Metabolism, Inborn Errors Arterial Occlusive Diseases Hyperlipidemias Heart Diseases Metabolic Diseases Myocardial Ischemia Vascular Diseases Arteriosclerosis |
Coronary Disease Metabolism, Inborn Errors Genetic Diseases, Inborn Hyperlipidemia, Familial Combined Cardiovascular Diseases Coronary Artery Disease Dyslipidemias Lipid Metabolism Disorders |
